Recurrent mutations refine prognosis in chronic lymphocytic leukemia

Leukemia

Volumn 29, Issue 2, 2015, Pages 329-336

  Baliakas, P ^a,b   Hadzidimitriou, A ^a,c   Sutton, L A ^a   Rossi, D ^d   Minga, E ^c   Villamor, N ^e   Larrayoz, M ^f   Kminkova, J ^g   Agathangelidis, A ^h,i   Davis, Z ^j   Tausch, E ^k   Stalika, E ^b   Kantorova, B ^g   Mansouri, L ^a   Scarfo L ^h,i   Cortese, D ^a   Navrkalova, V ^g   Rose Zerilli, M J J ^f   Smedby, K E ^l   Juliusson, G ^m   Anagnostopoulos, A ^b   Makris, A M ^c   Navarro, A ^e   Delgado, J ^e   Oscier, D ^j   Belessi, C ⁿ   Stilgenbauer, S ^k   Ghia, P ^h,i   Pospisilova, S ^g   Gaidano, G ^d   Campo, E ^e   Strefford, J C ^f   Stamatopoulos, K ^a,b,c   Rosenquist, R ^a   more..

^a UPPSALA UNIVERSITY   (Sweden)

^b G PAPANICOLAOU HOSPITAL   (Greece)

^c INFORMATION TECHNOLOGIES INSTITUTE   (Greece)

^d UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^e UNIVERSITY OF BARCELONA   (Spain)

^f UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^g UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^h VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

ⁱ SAN RAFFAELE HOSPITAL   (Italy)

^j ROYAL BOURNEMOUTH HOSPITAL   (United Kingdom)

^k UNIVERSITY OF ULM   (Germany)

^l KAROLINSKA INSTITUTE   (Sweden)

^m LUND UNIVERSITY   (Sweden)

ⁿ Nikea General Hospital Athens   (Greece)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIRC3 PROTEIN; MYELOID DIFFERENTIATION FACTOR 88; NOTCH1 RECEPTOR; PROTEIN; PROTEIN P53; SF3B1 PROTEIN; UNCLASSIFIED DRUG; NOTCH1 PROTEIN, HUMAN; PHOSPHOPROTEIN; SF3B1 PROTEIN, HUMAN; SMALL NUCLEAR RIBONUCLEOPROTEIN; TP53 PROTEIN, HUMAN;

ARTICLE; CANCER PROGNOSIS; CHROMOSOME 13Q; CHROMOSOME DELETION 13; CHRONIC LYMPHATIC LEUKEMIA; CODON; CYTOGENETICS; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; MAJOR CLINICAL STUDY; MISSENSE MUTATION; MUTATION RATE; PRIORITY JOURNAL; TRISOMY 12; AGED; EUROPE; FEMALE; GENE DELETION; GENETICS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; NUCLEOTIDE SEQUENCE; PROGNOSIS; RECURRENT DISEASE; SINGLE NUCLEOTIDE POLYMORPHISM; TIME;

AGED; CYTOGENETICS; DNA MUTATIONAL ANALYSIS; EUROPE; FEMALE; GENE DELETION; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; PHOSPHOPROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RECEPTOR, NOTCH1; RECURRENCE; RIBONUCLEOPROTEIN, U2 SMALL NUCLEAR; TIME FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84922529491     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.196     Document Type: Article

References (34)

1. Fabbri G, Rasi S, Rossi D, Trifonov V, Khiabanian H, Ma J et al. Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J Exp Med 2011; 208: 1389-1401.
2. Puente XS, Pinyol M, Quesada V, Conde L, Ordonez GR, Villamor N et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 2011; 475: 101-105.
3. Quesada V, Conde L, Villamor N, Ordonez GR, Jares P, Bassaganyas L et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat Genet 2012; 44: 47-52.
4. Wang L, Lawrence MS, Wan Y, Stojanov P, Sougnez C, Stevenson K et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med 2011; 365: 2497-2506.
5. Stilgenbauer S, Schnaiter A, Paschka P, Zenz T, Rossi M, Dohner K et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood 2014; 123: 3247-3254.
6. Schnaiter A, Paschka P, Rossi M, Zenz T, Buhler A, Winkler D et al. NOTCH1, SF3B1, and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG. Blood 2013; 122: 1266-1270.
7. Rossi D, Bruscaggin A, Spina V, Rasi S, Khiabanian H, Messina M et al. Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness. Blood 2011; 118: 6904-6908.
8. Cortese D, Sutton LA, Cahill N, Smedby KE, Geisler C, Gunnarsson R et al. On the way towards a 'CLL prognostic index': focus on TP53, BIRC3, SF3B1, NOTCH1 and MYD88 in a population-based cohort. Leukemia 2013; 28: 710-713.
9. Del Giudice I, Rossi D, Chiaretti S, Marinelli M, Tavolaro S, Gabrielli S et al. NOTCH1 mutations in +12 chronic lymphocytic leukemia (CLL) confer an unfavorable prognosis, induce a distinctive transcriptional profiling and refine the intermediate prognosis of +12 CLL. Haematologica 2012; 97: 437-441.
10. Jeromin S, Weissmann S, Haferlach C, Dicker F, Bayer K, Grossmann V et al. SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients. Leukemia 2014; 28: 108-117.
11. Oscier DG, Rose-Zerilli MJ, Winkelmann N, Gonzalez de Castro D, Gomez B, Forster J et al. The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial. Blood 2013; 121: 468-475.
12. Rossi D, Fangazio M, Rasi S, Vaisitti T, Monti S, Cresta S et al. Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia. Blood 2012; 119: 2854-2862.
13. Rossi D, Rasi S, Spina V, Bruscaggin A, Monti S, Ciardullo C et al. Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. Blood 2013; 121: 1403-1412.
14. Weissmann S, Roller A, Jeromin S, Hernandez M, Abaigar M, Hernandez-Rivas JM et al. Prognostic impact and landscape of NOTCH1 mutations in chronic lymphocytic leukemia (CLL): a study on 852 patients. Leukemia 2013; 27: 2393-2396.
15. Villamor N, Conde L, Martinez-Trillos A, Cazorla M, Navarro A, Bea S et al. NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome. Leukemia 2013; 27: 1100-1106.
16. Mansouri L, Cahill N, Gunnarsson R, Smedby KE, Tjonnfjord E, Hjalgrim H et al. NOTCH1 and SF3B1 mutations can be added to the hierarchical prognostic classification in chronic lymphocytic leukemia. Leukemia 2013; 27: 512-514.
17. Schuh A, Becq J, Humphray S, Alexa A, Burns A, Clifford R et al. Monitoring chronic lymphocytic leukemia progression by whole genome sequencing reveals heterogeneous clonal evolution patterns. Blood 2012; 120: 4191-4196.
18. Schwaederle M, Ghia E, Rassenti LZ, Obara M, Dell'Aquila ML, Fecteau JF et al. Subclonal evolution involving SF3B1 mutations in chronic lymphocytic leukemia. Leukemia 2013; 27: 1214-1217.
19. Landau DA, Carter SL, Stojanov P, McKenna A, Stevenson K, Lawrence MS et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 2013; 152: 714-726.
20. Trbusek M, Smardova J, Malcikova J, Sebejova L, Dobes P, Svitakova M et al. Missense mutations located in structural p53 DNA-binding motifs are associated with extremely poor survival in chronic lymphocytic leukemia. J Clin Oncol 2011; 29: 2703-2708.
21. Balatti V, Bottoni A, Palamarchuk A, Alder H, Rassenti LZ, Kipps TJ et al. NOTCH1 mutations in CLL associated with trisomy 12. Blood 2012; 119: 329-331.
22. Lopez C, Delgado J, Costa D, Conde L, Ghita G, Villamor N et al. Different distribution of NOTCH1 mutations in chronic lymphocytic leukemia with isolated trisomy 12 or associated with other chromosomal alterations. Genes Chromosomes Cancer 2012; 51: 881-889.
23. Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910-1916.
24. Gunnarsson R, Isaksson A, Mansouri M, Goransson H, Jansson M, Cahill N et al. Large but not small copy-number alterations correlate to high-risk genomic aberrations and survival in chronic lymphocytic leukemia: a high-resolution genomic screening of newly diagnosed patients. Leukemia 2010; 24: 211-215.
25. Agathangelidis A, Darzentas N, Hadzidimitriou A, Brochet X, Murray F, Yan XJ et al. Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies. Blood 2012; 119: 4467-4475.
26. Murray F, Darzentas N, Hadzidimitriou A, Tobin G, Boudjogra M, Scielzo C et al. Stereotyped patterns of somatic hypermutation in subsets of patients with chronic lymphocytic leukemia: implications for the role of antigen selection in leukemogenesis. Blood 2008; 111: 1524-1533.
27. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008; 111: 5446-5456.
28. Xu L, Hunter ZR, Yang G, Zhou Y, Cao Y, Liu X et al. MYD88 L265P in Waldenstrom macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allelespecific polymerase chain reaction. Blood 2013; 121: 2051-2058.
29. Rose-Zerilli MJ, Forster J, Parker H, Parker A, Rodriguez AE, Chaplin T et al. ATM mutation rather than BIRC3 deletion and/or mutation predicts reduced survival in 11q-deleted chronic lymphocytic leukemia: data from the UK LRF CLL4 trial. Haematologica 2014; 99: 736-742.
30. Shedden K, Li Y, Ouillette P, Malek SN. Characteristics of chronic lymphocytic leukemia with somatically acquired mutations in NOTCH1 exon 34. Leukemia 2012; 26: 1108-1110.
31. Gentien D, Kosmider O, Nguyen-Khac F, Albaud B, Rapinat A, Dumont AG et al. A common alternative splicing signature is associated with SF3B1 mutations in malignancies from different cell lineages. Leukemia 2014; 28: 1355-1357.
32. Rahal R, Frick M, Romero R, Korn JM, Kridel R, Chan FC et al. Pharmacological and genomic profiling identifies NF-kappaB-targeted treatment strategies for mantle cell lymphoma. Nat Med 2014; 20: 87-92.
33. Oscier DG, Gardiner AC, Mould SJ, Glide S, Davis ZA, Ibbotson RE et al. Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood 2002; 100: 1177-1184.
34. Krober A, Seiler T, Benner A, Bullinger L, Bruckle E, Lichter P et al. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 2002; 100: 1410-1416.